In endometrial cancer patients with MUC16 mutation, T-cell-mediated immune response was expressed in abundance, T-cell and CD8 + T-cell infiltration increased in the tumor microenvironment, and two interleukin-12 (IL-12)-mediated pathways were up-regulated in T cells and NK cells, suggesting that MUC16 mutation could promote anti-tumor immune response in patients. The gene discussed is MUC16; the disease is neoplasm.